German biotech CureVac has released preliminary data from its ongoing cooperation with UK drugmaker GSK on a new class of “transformative medicines” based on messenger...
CureVac and GSK have announced they are launching a Phase 1 clinical trial with their modified mRNA-based Covid 19 vaccine CV051, which would be recommended as a booster...
Pfizer and BioNTech are fighting back against CureVac’s lawsuit that asserts the makers of the Comirnaty-branded mRNA vaccine for Covid-19 infringed its patent.
Germany’s BioNTech is pushing back against allegations by compatriot CureVac that the company infringed its intellectual property in formulating its mRNA-based Covid-19...
In a vote of 21 in favor with one abstention, the US Food and Drug Administration’s advisory panel has recommended that the FDA approve Novavax’s Covid-19 vaccine...
What does 2022 hold for the biopharma industry? Which companies can play at the forefront in terms of products as well as business? Covid-19 will continue to be a...
Germany’s economics ministry has budgeted up to €2.9 billion ($3.14 billion) to ensure sufficient supply of mostly mRNA-based Covid-19 vaccines to be able to deal with...
CureVac is withdrawing its first-generation Covid-19 vaccine candidate, CVnCoV, from the current approval process with the European Medicines Agency. In a statement, the...
